Epistem, a UK-based biotechnology company, has partnered with Dr Matthew Hardman at The University of Manchester following which preclinical models for cutaneous wound healing, developed by Dr Hardman, will be transferred to Epistem.
Subscribe to our email newsletter
The Technology Strategy Board and Medical Research Council has awarded a Knowledge Transfer Partnership (KTP) grant to Epistem and The University of Manchester to optimise, validate and commercialise new preclinical assays for wound repair.
Epistem hopes the partnership will enable expansion of its existing portfolio of wound healing models and provide a broad, innovative service range.
Dr Hardman said the partnership represents an opportunity to realise the potential of their work.
Epistem managing director Catherine Booth said Dr Hardman would provide their customers access to cutting edge preclinical models.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.